Stambomycine

Presentation

The study of one Streptomyces ambofaciens bacteria strain has enabled the identification and characterization of a new macrolide complex:  stambomycines. They exhibit antibacteria activities against  Gram + bacteria, except for Mycobacterium smegmatis.

Stambomycines also show very promising antiproliferative activities  against the tested tumor cell lines (HT29, MCF7, H460 et PC3).  Results from cytotoxicity tests are also very favorable, since they are not more toxic than the reference molecule, the doxorubicine, which is one of the main substances used in anticancer chemotherapy. Analyses are currently being performed to  determine the antiproliferative action mechanism of these molecules. 

Competitive advantages

• Macrolides producted from Streptomyces ambofaciens bacteria;
• Efficient against Gram + bacteria;
• Antiproliferative activity.
  

Applications/Markets

• Antibiotics;
• Antitumor treatments;
• Agrifood components, agricultural products;
• Industrial decontaminant, disinfectant.
  

Intellectual property

• Patent WO 2011/009938;
• Collaboration sought: Licensing for the commercialization of new molecules;
• Readiness Level: Synthesis process at the laboratory scale. In vitro tests.